Please login to the form below

Not currently logged in
Email:
Password:

palbociclib

This page shows the latest palbociclib news and features for those working in and with pharma, biotech and healthcare.

Half of European cancer drug trials ‘biased’, says BMJ

Half of European cancer drug trials ‘biased’, says BMJ

That included Servier’s leukaemia treatment Oncaspar(pegaspargase), which had five studies deemed to be at risk, while others included Novartis’  Mekinist(trametinib; three studies) and Pfizer’s  Ibrance(palbociclib; two

Latest news

More from news
Approximately 7 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Engaging the digital healthcare professional Engaging the digital healthcare professional

    When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... Weeks later, following the NICE consultation period, the

  • Pharma deals during August 2013 Pharma deals during August 2013

    Palbociclib, which is the result of an early partnership with Pfizer and now being developed by Pfizer, is in phase III trials for advanced breast cancer and certain haematologic malignancies. ... If approved, Onyx will receive an 8 per cent royalty on

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics